Hepatobiliary neoplasm

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This study tests whether giving two drugs (ateganosine and cadonilimab) before surgery can safely shrink liver tumors in people with resectable hepatocellular carcinoma. About 60 participants will receive either one or both drugs before their operation. The main goal is to see if…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This study tests whether a personalized nursing program can prevent acute kidney injury (AKI) in people with liver cancer who undergo interventional therapy. Researchers first use a prediction model to classify patients into low, moderate, or high risk for AKI. Then, they provide…

This phase II trial investigates whether adding SHR-8068 to a two-drug regimen (adebrelimab and apatinib) can improve outcomes for people with liver cancer that can be surgically removed but has a moderate-to-high risk of coming back. Participants receive the drug combination bef…

This study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy (gemcitabine and cisplatin) in people with a rare, advanced liver cancer called combined hepatocellular-cholangiocarcinoma that cannot be removed by surgery or has spread. Ab…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 538 people with advanced biliary tract cancer that has worsened after prior treatments. The goal is to see if the new drug helps people live longer. The study is not yet recruiting.

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This study investigates whether regular blood tests can detect liver cancer earlier in people with type 2 diabetes who also have significant liver scarring. Participants are randomly assigned to either a surveillance group receiving specialized blood tests every six months or a s…

This study tests a surgery called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with certain pancreatic tumors who are at high risk for a dangerous leak after standard surgery. The procedure removes the entire pancreas and transplants the insulin-making…

This trial tests a treatment called Yttrium-90 radiation segmentectomy for people with liver cancer that can't be removed by surgery. Tiny radioactive beads are injected into the blood supply of the tumor to deliver targeted radiation. The study will enroll 64 participants to see…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This study tests a combination of targeted radiation (SBRT) and an experimental drug called QL1706 in 36 adults with advanced liver cancer that has worsened after one prior treatment. The radiation is given to liver tumors over five sessions, followed by QL1706 infusions every th…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This study tests a radiation treatment called SIRT (selective internal radiation therapy) using tiny radioactive beads delivered directly to liver tumors. The goal is to shrink tumors enough so that patients with liver cancer can qualify for a liver transplant or have surgery to …

This study tests a new planning method called multicompartment dosimetry (MCD) for TheraSphere, a treatment that delivers tiny radioactive beads to liver tumors. The goal is to give a higher radiation dose to the tumor while protecting healthy liver. Researchers will enroll 140 p…

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…

This study tests a treatment called NRT6003, which delivers tiny radioactive beads directly to liver tumors through a blood vessel. It is for people with liver cancer that has already been treated but not cured. The goal is to see if this single session of internal radiation can …

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This phase II trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—in 30 adults with advanced biliary tract cancer whose first treatment stopped working. The goal is to see if the combo can shrink tumors and improve sur…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study tests an experimental drug (PD-1/IL-2 bispecific antibody) given before a second surgery in 30 adults whose liver cancer returned early after initial curative surgery. The goal is to see if the drug can shrink or kill more cancer cells before the operation, potentially…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This phase II trial tests whether giving a mix of immunotherapy (durvalumab), chemotherapy (cisplatin and gemcitabine), and possibly a targeted drug (futibatinib) before surgery can improve outcomes for patients with resectable intrahepatic cholangiocarcinoma, a type of bile duct…

This trial tests a drug called HRX215 in 80 adults with colorectal cancer that has spread to the liver. Before surgery to remove liver tumors, patients often get a procedure (PVE) that blocks blood flow to the tumor area to encourage the healthy part of the liver to grow. HRX215 …

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can help people with advanced bile duct cancer live longer without their cancer growing. About 123 adults with untreated, inoperable bile duct cancer will be randomly assigned to …

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This early-phase trial tests a new drug called AB801, which blocks a protein (AXL) that helps cancers grow and resist treatment. It is given alongside chemotherapy and immunotherapy to people with bile duct or pancreatic cancer that is either borderline resectable, locally advanc…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This study tests a combination of two immunotherapy drugs (iparomlimab and toripalimab) plus bevacizumab and chemotherapy as a first treatment for advanced biliary tract cancer. It involves 32 adults aged 18-75 who have not had prior treatment for their advanced cancer. The goal …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a combination of four drugs (epalrestat, HAIC, donafenib, and tislelizumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery and who also have diabetes. The goal is to see if this approach can control the cancer for at …

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This study tests whether giving a combination of chemotherapy directly into the liver (HAIC) plus two drugs (camrelizumab and apatinib) before and after surgery can prevent liver cancer from returning in high-risk patients. About 208 people with resectable liver cancer and high-r…

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This phase 2 trial tests whether alternating between two chemotherapy regimens (mFOLFOX and mFOLFIRI) works better than using just one (mFOLFOX) as a second-line treatment for advanced biliary tract cancer. The study will enroll 130 adults whose cancer has progressed after first-…

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…

This study tests whether a newer, shorter metal stent works better than a standard plastic stent for opening blocked bile ducts in people with pancreatic cancer who need surgery. About 116 adults with operable or locally advanced pancreatic cancer and high bilirubin levels will b…

This phase 2 trial tests two oral drugs, lenvatinib and regorafenib, in 146 adults with advanced liver cancer that cannot be surgically removed and has worsened after initial immunotherapy. The study has two parts: one for patients with better liver function and one for those wit…

This Phase 3 trial tests a new drug, BL-M07D1, against standard chemotherapy in about 400 people with a specific type of advanced bile duct cancer (HER2-positive) that has stopped responding to platinum-based chemo. The goal is to see if BL-M07D1 can help people live longer. Part…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This study tests whether adding a special thermal therapy (which freezes and heats tumors) to standard targeted therapy and immunotherapy can help people with advanced liver cancer that cannot be removed by surgery. About 166 participants will be randomly assigned to receive eith…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This study tests if adding a targeted drug (becotatug vedotin) to standard chemotherapy and immunotherapy helps shrink tumors better than standard treatment alone in people with advanced bile duct cancer that has a specific gene change (EGFR mutation). About 164 adults with this …

This study tests a new drug combination for people with metastatic solid tumors that lack a gene called MTAP. The drugs, BMS-986504 and pemetrexed, aim to stop cancer cells from growing. The trial will check safety and how well the combo works in 72 participants.

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This phase 2 trial tests whether giving a combination of chemotherapy (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) before surgery can reduce tumor cells in patients with bile duct cancer at high risk of recurrence. About 34 adults aged 18-80 with resectabl…

This trial is testing a new way to treat intermediate and advanced liver cancer. It combines two liver-directed procedures (HAIC and TACE) with two drugs (apatinib and camrelizumab) to see if this approach works better than other combinations. The study will involve 315 adults wi…

This early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This phase 2 trial tests a combination of two targeted drugs (donafenib and sintilimab) plus chemotherapy delivered directly to the liver as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study will enroll 90 participants and measur…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This early-stage trial tests a new RNA-based drug called YMN-A02 in 10 people with advanced liver cancer that has stopped responding to standard treatments. The drug is designed to boost the immune system by blocking two cancer defenses at once. The main goal is to check safety a…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This early-phase study tests a new experimental drug (BRII-5395) combined with two approved cancer treatments (sintilimab and bevacizumab) in about 21 adults with advanced liver cancer linked to chronic hepatitis B. The main goal is to check safety and find the right dose, while …

This study looks at two types of metal stents (partially covered vs. bare) used to open blocked bile ducts in people with incurable cancer. The goal is to see which stent keeps the duct open longer and causes fewer problems. Sixty adults who already have a drainage tube will be r…

This early-stage trial tests a new vaccine that targets a specific protein found only in fibrolamellar liver cancer cells. The vaccine is combined with three other drugs to boost the immune system and block cancer growth. About 27 people with advanced disease who have already tri…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This phase 2 study tests whether adding the experimental drug zanzalintinib to the approved immunotherapy durvalumab can help people with advanced liver cancer live longer. Participants have already responded to an initial treatment of tremelimumab plus durvalumab and are now on …

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This study tests whether a combination of two drugs—adebrelimab (given by IV) and S-1 (taken as pills)—can help prevent bile duct cancer from returning after surgery. About 40 adults who had their cancer fully removed will receive the treatment for about 4 months and be monitored…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This phase 2 trial tests a combination of low-dose bevacizumab (a blood vessel growth blocker) and adebrelimab (an immunotherapy) along with two liver-directed procedures (TACE and HAIC) as a first treatment for people with unresectable hepatocellular carcinoma, a type of liver c…

This early-phase study will test whether adding peginterferon alfa-2b to standard antiviral drugs can help prevent hepatitis B-related liver cancer from coming back after surgery. About 156 adults aged 18 to 65 will receive either the combination or antivirals alone. Researchers …

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This study tests a device that keeps donor livers cool and oxygenated before transplant, aiming to reduce early liver problems. About 215 first-time liver transplant patients will receive a liver preserved with this method. The goal is to see if it lowers the risk of early graft …

This study tests whether adding Babao Dan Capsule (a traditional Chinese medicine) to standard antiviral treatment can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis who are at high risk. About 1,034 adults aged 18-65 with a specific TCM …

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This early-phase trial will test a new type of cell therapy called Meta10-GPC3 CAR-T in 27 people with advanced liver cancer that cannot be surgically removed. The treatment involves taking a patient's own immune cells, modifying them to recognize and attack liver cancer cells, a…

This phase II trial tests a combination of low-dose bevacizumab and atezolizumab (immunotherapy drugs) plus targeted chemotherapy delivered directly to the liver (TACE-HAIC) as a first treatment for people with unresectable hepatocellular carcinoma. About 38 participants will rec…

This study tests an experimental drug called WGI-0301 combined with lenvatinib in 80 people with advanced liver cancer who have already tried one treatment. The goal is to see if the combination is safe, tolerable, and shrinks tumors. It is an open-label, non-placebo trial across…

This study looks at whether starting denosumab early, along with a standard immunotherapy, can prevent bone problems like fractures or spinal cord compression in people with liver cancer that has spread to the bones. About 50 adults with liver cancer and bone metastases will be r…

This study looks at whether surgically removing the main liver tumor, followed by standard immune-based drug therapy, can help people with liver cancer that has spread to other organs live longer. About 280 adults with resectable liver tumors and at least one metastasis will be r…

This phase 3 trial tests whether adding targeted radiation or other local treatments to standard drug therapy can help people with liver cancer that has spread to a few spots outside the liver. All 400 participants first receive a combination of the immunotherapy sintilimab and t…

This study tests a combination of three drugs—firsekibart, tislelizumab, and lenvatinib—in people with advanced liver cancer that has a specific genetic change called a TP53 mutation. Participants must have already tried immunotherapy without success. The goal is to see if this d…

This phase 2 trial tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few other spots and no longer responds to first-line treatment. The goal is to see if this triple therapy can slow …

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This study tests whether giving a mix of chemotherapy, immunotherapy, and targeted therapy before surgery can reduce the risk of liver cancer returning in patients with high-risk features. About 100 participants will either receive the combination treatment followed by surgery, o…

This phase 2 trial tests VG2025, a modified herpes virus that targets and kills cancer cells while boosting the immune system, in 30 people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer). The virus is injected directly into tumors every four weeks. Ear…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This phase II trial tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can reduce the risk of liver cancer returning in patients with early-stage disease and narrow surgical margins. Sixty participants will be randomly assigned to receive the drug combina…

This study tests whether the drug regorafenib can help people with advanced liver cancer whose disease got worse after treatment with lenvatinib. About 24 adults will receive regorafenib and be monitored for how long their cancer stays under control and for side effects. The goal…

This phase 2 trial tests the cancer pill regorafenib in 20 adults with advanced liver cancer and moderate liver dysfunction (Child-Pugh B) whose disease worsened after first-line immunotherapy. Participants take regorafenib daily for 3 weeks on, 1 week off, until the cancer progr…

This study tests two drugs together—pucotenlimab (which helps the immune system fight cancer) and becotatugvedotin (which targets and kills cancer cells)—in people with advanced bile duct cancer that has not responded to prior treatment. The main goal is to see how many patients'…

This study tests a new treatment for people with advanced liver cancer that cannot be surgically removed. The treatment combines a type of internal radiation (Y-90) with two immunotherapy drugs (durvalumab and tremelimumab) and a targeted therapy pill (zanzalintinib). The goal is…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 30 adults with early-stage liver cancer (stage IB or IIA) will receive…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This study tests a new drug called WGI-0301 combined with the immunotherapy nivolumab in people with advanced liver or kidney cancer. The goal is to see if the combination is safe and can shrink tumors. About 230 adults aged 18 to 75 will take part, and the study does not use a p…

This study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…

This study tests whether combining local tumor treatments (TACE or ablation) with immunotherapy drugs (sintilimab and ipilimumab) before surgery can lower the chance of liver cancer coming back. It involves 105 adults with resectable liver cancer at intermediate-to-high risk of r…

This Phase 2 trial tests whether adding the immunotherapy drug envafolimab to standard chemotherapy (gemcitabine plus cisplatin) helps people with advanced biliary tract cancers live longer without their cancer growing. About 126 adults who have not had prior treatment for advanc…

This pilot study tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) after a standard liver cancer procedure called Y90 radioembolization can help control hepatocellular carcinoma. About 20 adults with liver cancer will be randomly assigned to one …

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This study tests a combination of two drugs (vebecotototo and putli monoclonal antibodies) in 44 people with advanced bile duct cancer that has a specific marker (EGFR) and has not responded to prior treatment. The goal is to see if the combination can shrink tumors and control t…

This study tests a new approach for people with liver cancer that cannot be removed by surgery. The treatment combines a procedure to grow the healthy part of the liver, chemotherapy directly into the liver, and two drugs (tislelizumab and lenvatinib) to shrink the tumor. The goa…

This study tests whether adding a traditional Chinese medicine called Biejia-Ruangan compound to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis. About 1,034 high-risk adults (based on a special score) will b…

This study tests whether combining two drugs—camrelizumab (an immunotherapy) and rivoceranib (a targeted therapy)—with or without local treatments like surgery or radiation can shrink tumors in people with advanced liver cancer that has spread to the lungs. About 32 participants …

This early-phase trial tests a new drug called MRG006A, combined with immunotherapy and targeted therapy, in 160 people with advanced hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery. The study aims to check safety, find the right dose, and se…

This phase 3 study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be enrolled. The main goal is to see if this app…

This Phase 2 trial tests whether adding personalized radiotherapy (PULSAR) and fecal microbiota transplants (FMT) to standard targeted-immunotherapy can reverse resistance in advanced liver cancer. About 64 patients whose cancer stopped responding to first-line treatment will be …

This study tests a new, affordable type of radioactive microsphere for treating liver cancer that cannot be removed by surgery. The microspheres are delivered directly to the tumor through a blood vessel, delivering radiation to kill cancer cells. The trial will enroll 18 adults …

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This phase II trial tests whether combining an immunotherapy drug (PD-L1 inhibitor) with chemotherapy and radiation can shrink advanced bile duct tumors enough to allow a liver transplant. The study will enroll 25 adults with locally advanced perihilar cholangiocarcinoma that can…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This study tests whether giving the immunotherapy drug atezolizumab before liver surgery can strengthen the body's immune response against liver cancer (hepatocellular carcinoma). About 30 patients will receive two doses before their operation. Researchers hope this approach migh…

This small study will test a new device that uses heat to destroy liver tumors in 20 people who cannot have surgery. The main goal is to see if the device is safe and how well it works at shrinking tumors after one month. Researchers will also check how the treatment affects the …

This study tests whether using a gentle suction tube (negative-pressure drainage) is better than placing a small plastic tube (stent) in the pancreas to prevent pancreatitis after removing tumors from the duodenum. About 132 adults with early-stage tumors will be randomly assigne…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests whether adding the drug Mitazalimab to standard chemotherapy helps people with advanced bile duct cancer live longer. About 160 adults whose cancer has spread or cannot be removed will receive either chemo alone or chemo plus Mitazalimab. Researchers will check s…

This study tests a combination of chemotherapy delivered directly to the liver, an oral targeted drug, and an immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors. The trial will enroll 30…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This phase 2 trial tests whether adding branched-chain amino acids (BCAAs) to the drugs lenvatinib and pembrolizumab helps adults with unresectable liver cancer live longer without their cancer worsening. About 234 participants will be randomly assigned to receive the standard tw…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This study looks at 100 liver cancer patients whose tumors shrank or disappeared after initial therapy. It compares two follow-up options: surgery to remove any remaining cancer, or continuing medication (maintenance therapy). The goal is to see which approach better prevents the…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This study tests a new combination of drugs (SH006 plus chemotherapy) against the standard drug regorafenib in 120 people with advanced liver cancer that has not responded to immunotherapy. The goal is to see if the new combo can slow cancer growth or improve survival. Participan…

This early-phase study tests a new drug called JSKN027 in 250 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study focuses on colorectal, lun…

This phase 3 trial compares two treatments for small liver cancer (tumors 5 cm or smaller): surgery to remove the tumor or a precise, high-dose radiation therapy called SBRT. About 312 adults with a single liver tumor will be randomly assigned to one of the two treatments. The st…

This study will test whether a deep learning computer model can help doctors decide which liver cancer patients should receive immunotherapy (PD-1 inhibitors) after surgery to prevent the cancer from returning. About 300 patients who have had their liver cancer completely removed…

This study looks back at medical records of 300 people with liver cancer that could not be removed by surgery. About 100 received a combination of local treatments (like TACE or radiation) plus targeted drugs and immunotherapy, aiming to shrink tumors enough for surgery. The othe…

This early-phase trial tests a new drug called TPD3310 in 112 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive weekly injections over 28-day cycl…

This study tests a three-part treatment for people with liver cancer that has spread into the main vein of the liver (portal vein tumor thrombus). Participants will receive radiation therapy, followed by two drugs (tislelizumab and anlotinib) to boost the immune system and block …

This study tests whether growing a patient's tumor cells in the lab (as organoids) can help doctors choose the most effective drugs after liver cancer surgery. 56 adults with high-risk features will have their tumor tested against several approved drugs. The goal is to see if thi…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This study tests whether growing a patient's tumor cells in the lab (called organoids) and testing different drugs on them can help doctors choose the most effective treatment for advanced liver cancer that cannot be removed by surgery. About 94 adults aged 18-70 will either rece…

This study tests a new way to choose cancer drugs for people with advanced biliary tract cancer that cannot be removed by surgery. Doctors will take a small sample of the tumor, grow it in the lab, and test different drugs to see which one works best. The goal is to see if this p…

This study tests a new combination of four treatments for people with liver cancer that cannot be removed by surgery and who also have high blood pressure in the liver (portal hypertension). The goal is to see if adding a blood-pressure drug (carvedilol) to standard cancer therap…

This phase II trial tests a personalized approach for people with advanced liver cancer that cannot be removed by surgery. Researchers will classify each patient's tumor by its fatty acid degradation (FAD) subtype and assign either a drug combination (camrelizumab plus apatinib) …

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests a new combination of treatments for people with a specific liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The treatment includes chemotherapy delivered directly to the liver, along with two oral and intravenous drugs. The goal i…

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This phase II trial tests whether giving the immunotherapy drug sintilimab along with targeted radiation before surgery can lower the risk of liver cancer returning. About 110 patients with resectable liver cancer will be randomly assigned to receive the combination therapy befor…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This study tests whether blocking the artery that feeds a bile duct tumor before surgery can make it possible to remove the cancer safely. It includes 33 adults with advanced bile duct cancer that currently cannot be operated on. The main goal is to see how many patients are aliv…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This study compares two treatment combinations for advanced liver cancer that cannot be removed by surgery. One group gets TACE (a procedure that blocks blood flow to the tumor and delivers chemo directly) plus immunotherapy and a targeted drug. The other group gets HAIC (a conti…

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…

This phase 2 trial tests a combination of sintilimab (an immunotherapy), bevacizumab (a targeted therapy), and chemotherapy (albumin-bound paclitaxel plus gemcitabine) as a first treatment for people with advanced bile duct cancer that cannot be surgically removed. The study aims…

This Phase 3 trial tests a new daily pill, TT-00420, against standard chemotherapy in 138 adults with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or mutation) and has worsened after first treatment. The study compares how long the cancer stays under…

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This phase 2 trial tests the drug lenvatinib as a first treatment for 50 adults with advanced liver cancer (HCC) who cannot have surgery or other curative treatments. The goal is to see if lenvatinib can control the cancer and improve survival. Participants must have measurable t…

This study tests a combination of three drugs—ivarmacitinib, camrelizumab, and apatinib—in 65 people with advanced liver cancer that has stopped responding to initial immunotherapy. The goal is to see if this triple therapy can shrink tumors or slow disease progression. Participa…

This study looks at whether combining local treatments (like targeted radiation or chemo beads) with newer drugs (anti-VEGF/TKIs and immune checkpoint inhibitors) can shrink liver tumors enough for patients to qualify for a transplant. Researchers will review records of 300 patie…

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests whether combining a liver-directed procedure (TACE) with an oral triple-drug cocktail works better than TACE plus standard targeted therapy and immunotherapy for people with liver cancer that cannot be surgically removed. About 222 participants will be randomly a…

This study tests whether taking a probiotic (Lactobacillus reuteri) before surgery can improve the effects of immunotherapy in people with liver cancer. About 40 adults with resectable liver cancer will either receive the probiotic plus immunotherapy or immunotherapy alone before…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This phase II trial tests whether combining a liver-directed procedure (TACE) with an immunotherapy drug (QL1706) before surgery, followed by more immunotherapy after surgery, can help patients with liver cancer that is too large or numerous for standard transplant criteria. The …

This study tests whether a lab test (3D-PTA) that checks which chemotherapy drugs work best on a patient's tumor can improve outcomes after bile duct cancer surgery. About 98 adults with stage II/III bile duct cancer will be randomly assigned to receive either standard capecitabi…

This study tests a new combination treatment for people with advanced liver cancer that cannot be surgically removed. The treatment includes a procedure that delivers chemotherapy directly to the tumor (TACE) plus two drugs that boost the immune system and block blood vessel grow…

This clinical trial is testing a new approach for people with advanced liver cancer whose first treatment stopped working. The study combines a targeted chemotherapy infusion (paclitaxel liposome) delivered directly into the liver artery with systemic drugs like immunotherapy and…

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This phase 2 trial tests whether adding radiotherapy to a combination of two drugs (QL1706 and bevacizumab) can shrink liver tumors that cannot currently be removed by surgery. The goal is to make enough tumors shrink so they can be surgically removed. The study will enroll 60 ad…

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…

This study is for people with advanced biliary tract cancer whose disease is stable after initial chemotherapy plus immunotherapy. It compares four different maintenance treatments: immunotherapy alone or combined with lenvatinib, venadaparib, or interleukin-2. The goal is to fin…

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…

This study tests a therapy that takes a patient's own immune cells, grows and strengthens them in a lab, and then gives them back to fight cancer. It is for people with advanced lung, liver, colorectal, or breast cancer that has spread. The goal is to see if this approach is safe…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This phase 2 trial tests whether a mix of immunotherapy (iparomlimab and tuvonralimab), chemotherapy (gemcitabine and oxaliplatin), and a targeted drug (lenvatinib) can shrink bile duct and gallbladder cancers enough to be surgically removed. About 29 adults with locally advanced…

This study compares two antiviral strategies—one using a single drug (TAF) and the other starting with two drugs (entecavir plus TAF) then switching to TAF alone—in 120 people with advanced hepatitis B-related liver cancer who are also receiving immunotherapy. The main goal is to…

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This study tests whether combining an immunotherapy drug (cadonilimab) with a chemotherapy pill (capecitabine) can prevent a rare mixed liver cancer from returning after surgery. About 75 adults who had their tumor completely removed but are at medium-to-high risk of recurrence w…

This study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…

This Phase 2 trial tests BB102, a targeted drug that blocks a protein called FGFR4, in 60 adults with advanced liver cancer that has not responded to standard treatments. Participants must have a specific genetic marker (FGF19 overexpression). The study will measure how well the …

This study tests a powerful combination of treatments for people with liver cancer that cannot be surgically removed. It combines two local therapies (TACE and SBRT) with an immunotherapy drug and a targeted pill (donafenib) as the first treatment. The goal is to shrink tumors an…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This study tests a procedure called irreversible electroporation (IRE), which uses short electrical pulses to kill liver cancer cells while leaving nearby healthy tissue unharmed. It is for people with early-stage liver cancer (HCC) who have good liver function. The goal is to se…

This study tests a procedure called irreversible electroporation (IRE), also known as Nanoknife, to treat liver tumors that have spread from colorectal cancer. IRE uses short electrical pulses to destroy cancer cells while sparing nearby blood vessels and bile ducts. The trial wi…

This Phase 2 trial tests whether adding a special immune cell infusion (GKL-006) to a standard procedure that blocks blood flow to tumors (TACE) can shrink liver cancers that cannot be removed by surgery. About 48 adults with unresectable hepatocellular carcinoma will receive the…

This study looks at 270 people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be removed right away. After initial chemotherapy (GOLP regimen), participants are split into three groups: one continues medication, one goes straight to surgery, and one use…

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This study looks at patients with advanced liver cancer that cannot be removed by surgery at first. They receive a combination of treatments—chemotherapy directly into the liver, anti-angiogenic drugs, and immunotherapy—to shrink the tumor. If the tumor shrinks enough to become r…

This early-stage trial will test the safety and tolerability of a new drug called SZ1003 in 12 adults with advanced hepatocellular carcinoma who have already tried and failed at least two standard treatments. Participants receive the drug by infusion every two weeks, and research…

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…

This study tests a combination of two drugs (adebrelimab and apatinib) in people with advanced liver cancer that has worsened after prior treatment. The goal is to see if the combination can shrink tumors. About 47 adults will receive the drugs intravenously and orally every thre…

This study tests whether adding a nerve-zapping procedure called endovascular denervation (EDN) to standard liver cancer treatments (TACE/HAIC and immune-targeted drugs) can improve outcomes for people with advanced liver cancer that has spread to the portal vein and stopped resp…

This study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…

This study tests whether giving a combination of two drugs—lenvatinib and losartan—after surgery can lower the chance of liver cancer returning in patients whose tumors show 'tumor budding,' a sign of aggressive disease. The drugs work by breaking down collagen barriers around ca…

This study tests a new approach for people with liver cancer that cannot be removed by surgery. Doctors will use tiny drug-coated beads to block blood flow to the tumor (a procedure called TACE) along with a targeted pill called Donafenib. The goal is to see if this combination c…

This early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…

This phase 2 trial tests whether adding a targeted chemo procedure (TACE) to standard immunotherapy can improve outcomes for people with unresectable liver cancer. About 90 participants will receive either atezolizumab/bevacizumab or durvalumab/tremelimumab plus TACE. The goal is…

This study tests whether targeted drugs or immunotherapies, chosen based on a patient's specific gene mutations, can shrink tumors and extend life in advanced cholangiocarcinoma (bile duct cancer). About 55 adults with unresectable, advanced disease and a targetable gene mutation…

This study tests a device that uses both freezing and heating to destroy liver tumors in people with liver cancer or colorectal cancer that has spread to the liver. The goal is to see if this approach improves how long patients live without their cancer growing, and whether it ac…

This phase 2 trial tests a combination of three drugs—disitamab vedotin, lenvatinib, and a PD-1 inhibitor—for people with HER2-positive advanced biliary tract cancer that cannot be removed by surgery. The study will enroll 65 participants to see how well the treatment shrinks tum…

This phase 2 trial tests whether the drug trilaciclib can protect bone marrow in 96 people with advanced bile duct or pancreatic cancer before they receive chemotherapy. The goal is to reduce serious side effects like low white blood cell counts, which can lead to infections. Par…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…

This phase 2 trial is testing a combination of three drugs—gecacitinib, donafenib, and a PD-1 inhibitor—as a second-line treatment for people with advanced liver cancer that did not respond to initial immunotherapy. The study will enroll 35 participants and measure how well the t…

This phase 2 trial is testing a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and a procedure that blocks the tumor's blood supply (TACE) in 41 people with advanced liver cancer. The goal is to see if this mix can keep the…

This phase 3 trial tests whether adding an experimental drug (TPST-1120) to standard immunotherapy and anti-angiogenic therapy helps people with advanced liver cancer live longer. About 740 adults whose cancer cannot be surgically removed or has spread will be randomly assigned t…

This Phase II trial tests an experimental drug called QLS31905 combined with chemotherapy, with or without another drug (QL2107), in 120 people with advanced biliary tract cancer that has a specific protein (CLDN18.2). The goal is to see if the combination shrinks tumors. Partici…

This phase 2 trial tests the drug cabozantinib in 60 adults with advanced liver cancer that worsened after first-line immunotherapy. The goal is to see if cabozantinib can stop or slow tumor growth for at least 6 months. Researchers will also look for blood and tissue markers tha…

This study tests whether a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy works better than a standard immunotherapy-plus-chemo regimen for advanced bile duct cancer. About 104 adults with inoperable or metastatic intrahepatic cholangi…

This trial investigates whether a special PET imaging tracer called [18F]FTT can help predict how well people with newly diagnosed bile duct cancer (cholangiocarcinoma) will respond to standard chemotherapy. The tracer binds to a protein called PARP1, which some tumor cells produ…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study will test an artificial intelligence system that screens for breast, liver, kidney, and bladder cancers using standard CT scans taken for other reasons. Researchers plan to enroll 100,000 participants to see if the AI can catch tumors earlier and help doctors reduce mi…

This study compares two devices (EYEMAX and SPYGLASS) used to take tissue samples from the bile duct to diagnose cancer. About 120 adults with bile duct narrowing will be randomly assigned to one device. The goal is to see which tool gives more accurate cancer diagnoses.

This study compares two contrast-enhanced ultrasound scoring systems (LI-RADS and ESCULAP) to see which one better detects recurrent liver cancer in 105 patients who have had surgery for hepatocellular carcinoma. The goal is to improve diagnostic accuracy for new liver lesions. P…

This study tests whether a special ultrasound technique, called contrast-enhanced subharmonic ultrasound, can predict if chemotherapy is working for stomach cancer that has spread to the liver. Currently, doctors wait about 2 months for CT or MRI scans to see tumor shrinkage. Thi…

This study will test whether using a contrast agent called Sonazoid during ultrasound can find early-stage liver cancer better than standard ultrasound alone. About 556 adults with liver cirrhosis will be scanned every 4 to 6 months. The goal is to see if this method catches more…

This study tests a special ultrasound technique called contrast-enhanced subharmonic ultrasound to see if it can predict whether chemotherapy is working for colorectal cancer that has spread to the liver. Currently, doctors wait about 2 months for CT or MRI scans to see if tumors…

This study tests a new imaging method called 68Ga-NYM207 PET/CT to see if it can safely and accurately detect liver cancer (hepatocellular carcinoma). About 100 adults with suspected or known liver cancer will receive the scan. The goal is to improve how doctors find and monitor …

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study is testing a new blood test that looks for specific DNA changes (methylation) to monitor if liver cancer comes back after treatment. Researchers will enroll 162 adults with liver cancer who have had surgery, transplant, ablation, or chemoembolization. The test's accura…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This study will use a special MRI machine to scan the liver for phosphorus and sodium signals in people with liver cancer and healthy volunteers. The goal is to see if these scans can tell the difference between cancerous and healthy tissue. 100 participants will be enrolled to t…

This early study will test a special imaging agent that targets a protein found on liver cancer cells. Six people with suspected or confirmed liver cancer will receive a low-dose radioactive tracer and then have a SPECT-CT scan. The goal is to see how the tracer moves through the…

This study tests a special imaging scan (Tc-GSA SPECT/CT) to see if it can predict liver failure after surgery for liver tumors. About 192 adults in Denmark will receive the scan before their operation. The goal is to compare this new method with standard tests and find the best …

This study tests a new type of PET scan (XH06 PET/CT or PET/MR) to see if it can diagnose liver cancer better than enhanced MRI. About 150 adults with suspected or confirmed liver cancer will get both scans, and results will be checked against tissue samples. The goal is to find …

This study tests a new way to use contrast-enhanced ultrasound (CEUS) to see if liver cancer treatment (ablation) worked. Researchers will compare the new CEUS criteria with standard CT or MRI scans in 200 adults. If accurate, this could make follow-up safer and easier by avoidin…

This study compares two ways to diagnose bleeding problems during surgery: a quick bedside test (viscoelastic test) and standard lab tests. The goal is to see which method gives faster results, helping doctors treat bleeding sooner. About 210 adults having high-risk surgeries (li…

This study looks at whether measuring a protein called TREM-1 in liver tissue can help doctors better predict how patients with severe alcoholic hepatitis will do. Researchers will compare TREM-1 levels in 300 people—half with alcoholic hepatitis and half with other liver disease…

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …

This phase II trial tests whether a low dose of the cancer drug erlotinib can prevent liver cancer in 60 adults with advanced liver fibrosis or cirrhosis. Participants will take either erlotinib or a placebo daily for a set period. The study will measure changes in a blood protei…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether taking a low-dose aspirin (100 mg) every day can prevent liver cancer in people with cirrhosis, a condition that raises cancer risk. About 890 adults from Australian hospitals will take aspirin or a placebo for 4 years while continuing their regular check…

This study tests whether a natural supplement called SAMe can help prevent liver cancer in people with advanced fatty liver disease (MASLD) and cirrhosis. About 94 adults will receive either SAMe or a placebo for 12 months. Researchers will measure changes in a blood test that pr…

This study in Zimbabwe will screen women of childbearing age and high school students for HPV and Hepatitis B, then offer vaccines to those who are eligible. It also includes cognitive behavioral therapy for mental health issues. The goal is to see if this combined approach can p…

This study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This study explores whether a personalized music therapy session, called music-assisted relaxation and imagery (MARI), can reduce pain and change gene activity in people recovering from open surgery for stomach, pancreas, bile duct, liver, or peritoneal cancer. Participants will …

This study compares two ways to drain blocked bile ducts in people with cancer near the liver. One method places a tube across the blockage into the intestine, while the other uses a metal stent that stops short of the intestine. The goal is to see which approach causes fewer com…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This early study tests an augmented reality (AR) system that overlays a tumor's image onto the liver during keyhole surgery. Six adults scheduled for liver tumor removal will participate. The goal is to see if the AR guidance helps surgeons remove tumors more completely and safel…

This study tests whether scheduled meditation using the Headspace app can improve recovery after pancreatectomy (surgery to remove part of the pancreas). Seventy patients will be asked to meditate regularly before and after surgery, and researchers will track pain, anxiety, sleep…

This study looks at whether using a drug combination without opioids during anesthesia can lower the chance of confusion (delirium) after surgery in people 65 and older having gastrointestinal surgery. About 174 participants will be randomly assigned to receive either opioid-free…

This study tests whether giving lidocaine through a vein during and after liver surgery can reduce side effects like nausea, vomiting, and breathing problems caused by opioid painkillers. About 312 adults having planned open liver surgery will be randomly assigned to receive eith…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This study tests whether offering free rideshares, hotel stays, and meal delivery helps low-income liver cancer patients start treatment sooner. About 75 uninsured or underinsured adults with liver cancer will be randomly assigned to receive these social supports plus usual patie…

This Phase 2 trial tests whether a drug called nanocrystalline megestrol acetate can help people with advanced liver cancer who are losing weight and appetite. About 88 patients will receive either the drug or a placebo for 12 weeks while also getting standard cancer therapy. The…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study tests whether electroacupuncture (mild electrical pulses through thin needles) can help patients whose stomachs stop working properly after surgery for digestive tract tumors. Seventy-six adults who had such surgery and developed gastroparesis (stomach paralysis) will …

This study tests a web-based program designed to help advanced cancer patients manage symptoms like depression, pain, fatigue, and sleep problems, while also supporting their caregivers. The program combines online tools with guidance from healthcare professionals. Researchers wi…

This study tests whether ondansetron, a drug typically used for nausea, can lower the risk and severity of side effects from immunotherapy in people with liver cancer. About 134 patients will receive ondansetron alongside their standard cancer treatment. The goal is to see if thi…

This study tests if inflating a small balloon in the stomach during surgery can prevent nausea, vomiting, and slow stomach emptying after pancreatic tumor removal. About 70 adults will be randomly assigned to get the balloon procedure or standard surgery. Researchers will track r…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether a probiotic called Clostridium butyricum CBM588 can reduce diarrhea and improve quality of life in people who have had their pancreas removed due to cancer or other growths. About 158 patients will take either the probiotic or a placebo for three months a…

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This study looks at whether adding a special form of megestrol acetate to standard treatment can help improve appetite and body weight in people with advanced liver cancer who are experiencing cachexia (severe weight loss and muscle wasting). About 68 participants will be randoml…

This study looks at whether adding a special behavioral support program to standard medical care can help people with liver cancer that cannot be removed by surgery. About 193 adults will be split into two groups: one gets the support program (including in-person sessions and a W…

This trial tests a new way to place plastic stents in the bile duct for people with jaundice caused by cancer near the liver. The standard method places the stent across the bile duct opening, while the new method places it above the opening without cutting the muscle. The study …

This study looks at whether warming the contrast dye to body temperature (37°C) before injecting it during an ERCP procedure can lower the chance of infection (cholangitis) in people with hilar cholangiocarcinoma (a type of bile duct cancer). About 100 adults aged 18-90 who need …

This study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…

This study tests a device called histotripsy, which uses focused ultrasound to break up tumors without cutting the skin. It is for people with abdominal tumors that cannot be surgically removed and are causing symptoms like pain. The goal is to see if the treatment improves quali…

This study tests whether adding a traditional Chinese herbal pill called Yueju to standard cancer therapy can improve quality of life for people with advanced biliary tract cancer. About 210 adults will be randomly assigned to get either the pill or a placebo, without knowing whi…

This study explores whether a special imaging technique called parenchymal blood volume (PBV) imaging can detect changes in blood flow within liver tumors after giving a drug called nitroglycerin. The drug is commonly used for heart conditions but may temporarily increase blood f…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study will examine whether certain workplace chemicals or tasks increase the risk of biliary tract and pancreatic cancers. Researchers will compare detailed work histories of 210 cancer patients from two earlier trials with healthy volunteers. The goal is to identify occupat…

This observational study will use bedside ultrasound to measure the diaphragm—the main breathing muscle—in 120 adults with liver cirrhosis and compare them to healthy volunteers. Researchers want to see if cirrhosis weakens the diaphragm and if removing fluid from the belly impro…

This study aims to create a score that predicts the risk of infection within 30 days after a liver transplant. Researchers will collect blood samples from 279 liver transplant patients before and after surgery to measure immune markers. The goal is to combine these markers with o…

This study tests whether a digitally supported prehabilitation program is feasible for patients awaiting major surgery for cancers of the pancreas, liver, stomach, or esophagus. The program includes supervised exercise, nutritional counseling, psychological support, and digital t…

This study will collect and analyze medical records from about 4,000 adults diagnosed with liver cancer (hepatocellular carcinoma) in Middle Eastern and North African countries between 2015 and 2023. Researchers want to understand what causes the cancer, how it is treated, and wh…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study looks back at data from 562 people who received a liver transplant for liver cancer (hepatocellular carcinoma) at hospitals in France, Canada, and Belgium. The goal is to create a better scoring system that considers tumor shrinkage before transplant, cancer growth whi…

This study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …

This study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…

This study looks at whether lifestyle changes can reduce the risk of liver cancer in people already at high risk. Researchers will track changes in bile acids, gut bacteria, and liver health in 90 adults aged 50-90. The goal is to see if simple adjustments can make a lasting diff…

This study tests whether an artificial intelligence (AI) model can predict how well liver cancer patients will respond to a combination of treatments, including a procedure called TACE, immunotherapy, and targeted therapy. Researchers will analyze medical images and other data fr…

This large French study will follow 1,810 adults receiving their first liver transplant to see if the way the donor liver is removed affects outcomes. The main focus is on avoiding artery and bile duct complications for three years after transplant. The goal is to identify the be…

This study will test whether an artificial intelligence (AI) model can help doctors decide between surgery and microwave ablation for people with early-stage liver cancer. The AI will analyze images from contrast-enhanced ultrasound and MRI scans to predict the risk of cancer ret…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study will follow 1,000 adults who have liver or bile duct surgery at one hospital in Italy. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand what affects recovery and long-term health after these opera…

This study looks at whether non-diabetic patients who have pancreas surgery can safely avoid routine insulin afterward. About 290 adults will be randomly assigned to receive either standard insulin or no insulin after surgery. The goal is to see if skipping insulin keeps blood su…

This study looks at whether a thorough health assessment before liver surgery can help older patients (70+) have fewer serious complications and recover better. Researchers will give 242 participants a special geriatric evaluation that checks frailty, memory, nutrition, and daily…

This trial looks at whether keeping or removing a drainage tube (PTCD catheter) during pancreatic surgery leads to fewer complications. About 100 patients with jaundice from tumors will be randomly assigned to one of two groups. The main goal is to see which approach reduces seri…

This study will examine stored tumor samples from 244 people diagnosed with biliary tract cancer in the last 15 years. Researchers will measure five specific markers (CLDN18.2, HER2, TROP2, PD-L1, and B7-H4) to see how common they are and how they relate to patient outcomes. The …

This study will use artificial intelligence to analyze CT scans and medical data from 400 liver cancer patients to predict who will respond to a common drug combination (atezolizumab and bevacizumab). The goal is to create a non-invasive tool that helps doctors choose the best tr…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study aims to learn if blood tests for cancer DNA (ctDNA) and patient-reported quality of life can help doctors predict how bile duct cancer will progress and whether treatments are working. Researchers will collect blood samples and surveys from 300 patients with curable or…

This study watches 200 adults with intermediate-stage liver cancer to see which treatments doctors actually use and how long patients survive. It does not test a new drug or procedure. The goal is to learn from real-world care to help guide future treatment decisions.

This study tests whether a special catheter called TriNav can deliver more radiation beads (Y90 microspheres) to liver tumors while reducing exposure to healthy liver tissue. Twenty adults with unresectable liver tumors will receive the standard radioembolization procedure using …

This study aims to create detailed computer models, or 'virtual twins,' of people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). By analyzing data from over 7,700 adults, researchers hope to better understand how the disease progresses and predict who migh…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…

This study tests whether personalized 3D liver models help surgeons plan major liver surgery more accurately. 25 adults having liver resection will get a 3D model before surgery. After surgery, the predicted and actual removed liver volumes are compared. The goal is to reduce the…

This study will watch how doctors use a special camera (endoscopic ultrasound) to diagnose suspected pancreatic or bile duct diseases in 2500 adults across Lombardy, Italy. The goal is to see how accurate the procedure is, how safe it is, and how quickly patients get a final diag…

This study looks at whether blood tests can predict how well liver cancer responds to a standard treatment called TACE. Researchers will collect blood samples from 60 adults with liver cancer before and after TACE, then compare the results with CT or MRI scans. The goal is to see…

This study aims to create a 3D model of the bile ducts using MRI and CT scans, along with an AI tool to help doctors guide a camera during a procedure called ERCP. The goal is to improve safety and accuracy. The study will use existing medical images from 100 adult patients who h…

This study will follow 154 older adults with type 2 diabetes who are scheduled for liver tumor surgery. Researchers will measure brain glucose metabolism using a PET scan before surgery and then check for delirium (sudden confusion) for a week after. The goal is to see if lower b…

This study looks at whether a blood test that detects tiny bits of tumor DNA (called minimal residual disease) can predict if liver cancer will come back after surgery. Researchers will test 276 patients before and after surgery to see if the test can also identify who might bene…

This study will create a biobank by collecting blood, tissue, and bile samples from 300 adults with liver, bile duct, or pancreatic tumors, as well as from people with benign conditions and healthy volunteers. No experimental treatments or extra procedures are involved—samples ar…

This study looks at whether getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves outcomes for people with liver cancer. Researchers will review medical records of 200 patients in Austria to compare response rates, survival, and side effects …

This trial compares two techniques used when standard bile duct access fails during ERCP: pre-cut sphincterotomy and the double guidewire technique. Researchers will enroll 840 adults with difficult bile duct cannulation to see which method is safer and more successful. The goal …

This study looks at stored liver biopsy samples from 30 people with MASH (a fatty liver disease) to see if a protein test can predict who will develop liver cancer within 15 years. Half of the participants later got liver cancer, and half did not. Researchers will compare the pro…

This study aims to find out how often a rare genetic condition called alpha-1 antitrypsin deficiency (AATD) occurs in people who develop liver cancer (hepatocellular carcinoma) but do not have cirrhosis or other known causes like hepatitis or heavy drinking. Researchers will look…

This study will follow 75 adults with advanced liver cancer who are already receiving immune checkpoint inhibitors as part of their regular care. Researchers will track how long patients live and how long the cancer stays under control. The goal is to better understand the real-w…

This study reviews past medical records of 300 people who had surgery for a rare and aggressive bile duct cancer called hilar cholangiocarcinoma. It aims to see if also removing nearby blood vessels during the operation helps patients live longer and have fewer complications. The…

This study will look at how a single 30-minute bike ride changes levels of certain liver proteins (FGF21 and follistatin) in 12 people with liver cancer. Researchers want to understand how exercise affects the body in these patients, which could lead to better exercise recommenda…

This study will look back at medical records of 100 people with a rare complication of liver cancer called rupture, where the tumor breaks open. Researchers want to find out how common this is, what raises the risk, and how long people live after it happens. The goal is to better…

This observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…

This observational study will measure Omega-6 fatty acid levels in the blood of 100 adults — half with liver cancer and half without — to see if there is a connection. No drugs or treatments are given. The goal is to understand if these fats are linked to the presence or severity…

This study looks at two different lengths of time for stopping blood flow to the liver during surgery for liver cancer. 600 adults will be randomly assigned to either a 15-minute or 45-minute pause in blood flow. The goal is to see if the longer pause is just as safe and does not…

This study compares two types of radiation therapy—body gamma knife and VMAT—for people with primary liver cancer who cannot have or refuse surgery. Researchers will look at how well each method targets the tumor and how much it affects nearby organs. The goal is to help patients…

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…

This observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …

This study looks at tiny particles in the blood, called extracellular vesicles, to see if they can predict serious liver problems like liver failure or liver cancer. Researchers will collect blood samples from 845 people, including healthy volunteers, diabetes patients, and those…

This study will test whether measuring liver tumor volume with CT scans can better assess how well two common treatments—TACE and microwave ablation—are working. Researchers will enroll 66 adults with liver cancer who cannot have surgery. The goal is to improve how doctors track …

This study will follow 200 adults undergoing surgery for liver, esophagus, or pancreatic cancer. Researchers want to see how patients' expectations before surgery relate to their pain, painkiller use, and recovery afterward. The goal is to learn how to better manage pain and impr…

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…

This study looks at whether an improved endoscopic ultrasound (EUS) can better find cancer in lymph nodes of people with bile duct cancer. About 250 patients with presumed resectable cancer will get the enhanced EUS before surgery. The goal is to see how many patients are spared …

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…

This study will analyze data from 2000 liver cancer patients to see how well interventional therapy combined with systemic drugs (like targeted therapy and immunotherapy) works in real life. Researchers will look at differences in outcomes and side effects, and use machine learni…

This study looks at a type of liver surgery called volume-restricted resection for patients with a rare bile duct cancer (perihilar cholangiocarcinoma) whose liver is too small after standard surgery. Researchers will follow 300 patients who get this surgery or non-surgical care …

This study will look at 150 infants and children aged 1 month to 4 years who are admitted to a hospital gastroenterology unit with a gastrointestinal disease. The goal is to find out how common electrolyte disturbances (like low sodium or potassium) are in these children. By meas…